Advertisement

Topics

Sanofi Expands MS Portfolio With BTK Inhibitor From Principia

12:38 EST 9 Nov 2017 | SCRIP

The French pharma adds the Phase I candidate to its Lemtrada follow-on for multiple sclerosis development, while Principia will use...

      

Related Stories

 

Original Article: Sanofi Expands MS Portfolio With BTK Inhibitor From Principia

NEXT ARTICLE

More From BioPortfolio on "Sanofi Expands MS Portfolio With BTK Inhibitor From Principia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...